More Trouble for Cepheid MRSA Test as Abaxis Sues for Patent Infringement
July 15, 2010
More Trouble for Cepheid MRSA Test as Abaxis Sues for Patent Infringement
Abaxis claims that Cepheid's PCR-based blood test for methicillin-resistant Staphylococcus aureus infringes its sample prep patents. In response, Cepheid has filed a counterclaim denying the alleged infringement and asking the court to find that Abaxis' patents are invalid.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Cepheid Recalls MRSA Blood Culture Test for Second Time; Company, Analysts Unconcerned
January 12, 2012 / PCR Insider - Q&A: UK Hospitals Find Cepheid's Xpert MRSA Test at Point of Care Can Shave Hours Off Time-to-Result
December 10, 2009 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - In Cepheid v. Roche IP Suit, Court Delays Hearing on One Patent, Dismisses Second Patent from Case
January 18, 2013 / GenomeWeb Daily News - Cepheid's Q1 Revenues Grow on Strong Clinical Reagent Sales; Analysts 'Unconcerned' with Net Loss
April 26, 2012 / PCR Insider